

## WINTER 2012 ISSUE: FEBRUARY 16, 2012

2011 was a very productive year for Third Rock and our portfolio companies, and 2012 is off to an excellent start. In this edition of our e-newsletter, we are pleased to share some of the exciting highlights from the end of 2011 and the first few weeks of the new year.

### SPOTLIGHT: BEYOND GREAT

Last fall we held our first ever bi-annual Leadership Summit, where we hosted 14 of our portfolio company CEOs for an offsite event that encouraged active discussion and dialog focused on aspects of creating stakeholder value across these transformational companies. More than ever before, our CEOs were able to collaborate and share insights and experiences that will be invaluable to their companies as they grow and advance key programs toward value inflection points. The Beyond Great Program continues to foster this close collaboration and knowledge sharing with our quarterly Cambridge-based CEO Breakfast Series. We are excited to see that our San Francisco-based CEOs will be holding their first Breakfast Series in March.



"Beyond Great is an exceptional program. In essence, Third Rock has established an intellectual community to support cross-company information sharing and opportunities for us to learn from each other as first-time CEOs. Now, in addition to the operational experience I have long valued within Third Rock, I can access and leverage the broad network of talent within the Third Rock portfolio companies, and the synergies are tremendous."

- *David Schenkein, M.D., CEO of Agios Pharmaceuticals*

### PORTFOLIO COMPANY NEWS

Over the last several months, we added five new companies to our portfolio and saw several others achieve important milestones in their evolution.

#### NEW INVESTMENTS

Through the end of 2011 and beginning of 2012, we added exceptional companies to our portfolio that have the potential to change the lives of patients in multiple disease categories.

- In October, Third Rock launched [SAGE Therapeutics](#), led by interim CEO and Third Rock partner Kevin Starr, to address CNS disorders with critical unmet needs, and in November, we launched metabolic disease-focused company, [Ember Therapeutics](#), led by interim CEO and Third Rock partner Lou Tartaglia.
- Earlier last fall, we invested in the Series B financing of [TOPICA Pharmaceuticals](#), a Phase 2/3 company focused on developing the first highly effective, safe and convenient topical treatment for onychomycosis, as well as in the Series A financing of [Allena Pharmaceuticals](#), which was founded by former Alnara executives and top-tier venture investors Bessemer Venture Partners and Frazier Healthcare.
- Notably, in January, Third Rock and Sanofi announced the launch of [Warp Drive Bio](#), creating a strategic partnership to discover and develop natural products using genomic technology. Warp Drive was the brainchild of Third Rock partner Greg Verdine, who serves as the company's interim CSO. Third Rock partner Alexis Boris negotiated the collaboration with Sanofi and serves as Warp Drive's interim CEO.



#### FINANCING/DEALS

This winter, our portfolio companies announced multiple strategic partnerships and secured financing from new investors in order to continue building their innovative companies.



- In October, [Foundation Medicine](#) announced its expanded Series A with new investors Kleiner Perkins and Google Ventures, as well as its fourth major pharmaceutical alliance with Johnson & Johnson Pharmaceutical Research and Development.



- Also that month, [Agios Pharmaceuticals](#) announced that its cancer metabolism collaboration with Celgene was extended ahead of schedule, resulting in a \$20 million payment to Agios. In November, Agios secured \$78 million in an oversubscribed Series C financing, adding several new investors, including three leading, large public investment funds.



- [Constellation Pharmaceuticals](#) announced in January that it has entered into a major strategic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to launch a broad collaboration based on the science of epigenetics and chromatin biology to discover and develop innovative treatments for cancer and other serious diseases.

#### DATA/CLINICAL MILESTONES

Over the last few months, many of our portfolio companies released exciting data at medical meetings, published studies in top-tier peer-reviewed journals and achieved significant clinical milestones, revealing tremendous potential for new treatments and diagnostics for patients.

- [Foundation Medicine](#) presented data on its comprehensive cancer diagnostic test at the 2011 European Multidisciplinary Cancer Congress in September, while [Zafgen](#) presented data at The Obesity Society's 29th Annual Scientific Meeting that month.
- [NinePoint Medical](#) announced new data on its innovative optical frequency domain imaging technology at the 19th UEGW meeting and received FDA 510(k) clearance for the Nvision VLE Imaging System.
- [TARIS Biomedical](#) initiated a Phase 2 clinical study with LIRIS in interstitial cystitis patients in November.
- Additionally, [Constellation Pharmaceuticals](#) published a paper in the *Proceedings of the National Academy of Sciences* (PNAS) demonstrating pharmacological suppression of MYC, a key cancer-causing gene.
- In January, [Ember Therapeutics](#) announced the publication of brown fat biology data in the journal *Nature*.

#### PEOPLE

Third Rock and our portfolio companies have continued to expand our teams with outstanding leaders who have a passion for making a difference and leading disruptive technologies.

- [Rhythm](#) strengthened its management team by naming Keith M. Gottesdiener, M.D., Chief Executive Officer and Lex Van der Ploeg, Ph.D., Chief Scientific Officer.
- In October, [Zafgen](#) appointed business development veteran Frances K. Heller to its Board of Directors.
- Recent appointments to the role of Chief Scientific Officer include Albert J. Robichaud, Ph.D., at [SAGE Therapeutics](#), Christoph Lengauer, Ph.D., at [Blueprint Medicines](#), and Henry Lowman, Ph.D., who was promoted to the position at [CytomX Therapeutics](#).
- [Third Rock](#) welcomed Principal Neil Kumar, Ph.D., to the San Francisco office in October.